Vaccines Articles
A recent Canadian study showed that the use of influenza vaccine was associated with a lower risk of major adverse cardiovascular events.
A recent study showed that a universal flu vaccine induced levels of anti-flu antibodies 34 times higher in mice and 10 times higher in ferrets compared with a traditional vaccine.
A study conducted by researchers at the Centers for Disease Control and Prevention found that pregnant women can safely receive the meningococcal vaccine Menactra.
Researchers at Boston Children’s Hospital have identified a potent compound that activates immune responses in newborns’ white blood cells substantially better than anything previously tested, and that could make vaccines effective right after birth.
Results from a large clinical trial of Sanofi Pasteur’s Fluzone High-Dose showed that the influenza vaccine was 24.2 percent more effective against lab-confirmed flu than the traditional vaccine dose in adults 65 and older.
Novavax Inc. announced positive preclinical data for its virus-like particle (VLP) vaccine candidate against A(H7N9) influenza.
Novovax Inc.’s quadrivalent seasonal influenza virus-like particle (VLP) vaccine demonstrated the company’s PhaseII clinical trial’s primary endpoint of safety and immunogenicity of three ascending dose levels.
A recent study conducted to evaluate barriers to pregnant women’s uptake of the influenza vaccine found that the decline in vaccination among this population was due to lower levels of knowledge and unfavorable attitudes regarding the vaccine’s safety and efficacy.
A study by researchers at RTI International and the U.S. Centers for Disease Control and Prevention showed that two-dimensional barcodes on vaccine product labels would enhance the safety of the U.S. immunization system and save more than $300 million by 2023.
The U.S. Food and Drug Administration has approved two new quadrivalent influenza vaccines (IIV4s).
A total of 4,659 adults aged 18 years or older were randomized to receive a single dose of inactivated quadrivalent influenza vaccine (IIV4) from one of three production lots or an inactivated trivalent influenza vaccine (IIV3) containing either a B/Victoria or B/Yamagata strain.
The first vaccine to protect children against the enterovirus 71, or EV71, that causes hand, foot and mouth disease has been developed by Chineses scientists at Beijing Vigoo Biological.